XML 40 R34.htm IDEA: XBRL DOCUMENT v3.19.3
Share Capital (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jul. 31, 2018
May 31, 2018
Mar. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Sep. 30, 2018
Sep. 09, 2019
Share Capital [Line Items]                  
Sale proceeds of common shares               $ 102,842  
Gain on termination of collaboration agreement         $ 4,398     $ 4,398  
Inducement Plan [Member]                  
Share Capital [Line Items]                  
Common shares reserved for issuance                 400,000
Series1 Preferred Shares                  
Share Capital [Line Items]                  
Conversion of shares 1,852,000                
Common Shares [Member]                  
Share Capital [Line Items]                  
Conversion of shares 1,852,000                
BVF Partners L.P [Member] | Exchange Agreement [Member]                  
Share Capital [Line Items]                  
Estimated weighted average cancellation price per share of common stock         $ 7.61        
BVF Partners L.P [Member] | Exchange Agreement [Member] | Series1 Preferred Shares                  
Share Capital [Line Items]                  
Shares issued         2,868,000        
Preferred shares convertible into common shares         one-for-one        
Common shares issued on conversion of preferred stock         1        
Maximum beneficial ownership limitation percentage for conversion of common stock issued and outstanding         9.99%        
Maximum beneficial ownership limitation upon notice, percentage for conversion of common stock issued and outstanding         19.99%        
Maximum beneficial percentage hold for conversion of number Of common stock issued and outstanding         5.00%        
Minimum beneficial percentage hold for conversion of number Of common stock issued and outstanding.         5.00%        
BVF Partners L.P [Member] | Exchange Agreement [Member] | Common Shares [Member]                  
Share Capital [Line Items]                  
Shares issued         2,868,000        
Common Shares [Member]                  
Share Capital [Line Items]                  
Shares issued           6,100,000 3,440,000    
Conversion of shares           1,300,000      
Stifel [Member] | At-The-Market Equity Offering [Member]                  
Share Capital [Line Items]                  
Sale proceeds of common shares       $ 29,200          
Stifel [Member] | At-The-Market Equity Offering [Member] | Maximum [Member]                  
Share Capital [Line Items]                  
Sale proceeds of common shares       $ 30,000          
Stifel [Member] | At-The-Market Equity Offering [Member] | Common Shares [Member]                  
Share Capital [Line Items]                  
Shares issued       3,440,000          
Jefferies and Stifel [Member] | At-The-Market Equity Offering Sales Agreement [Member]                  
Share Capital [Line Items]                  
Sale proceeds of common shares     $ 14,820            
Jefferies and Stifel [Member] | Maximum [Member] | At-The-Market Equity Offering Sales Agreement [Member]                  
Share Capital [Line Items]                  
Sale proceeds of common shares     $ 50,000            
Jefferies and Stifel [Member] | Common Shares [Member] | At-The-Market Equity Offering Sales Agreement [Member]                  
Share Capital [Line Items]                  
Shares issued     1,600,000            
Jefferies and Stifel [Member] | Underwritten Public Offering [Member]                  
Share Capital [Line Items]                  
Sale proceeds of common shares   $ 59,220              
Jefferies and Stifel [Member] | Underwritten Public Offering [Member] | Common Shares [Member]                  
Share Capital [Line Items]                  
Shares issued   4,500,000              
Shares price   $ 14.00       $ 14.00   $ 14.00  
Teva [Member]                  
Share Capital [Line Items]                  
Collaborative development and license agreement termination date         Mar. 31, 2018        
Teva Canada Limited [Member]                  
Share Capital [Line Items]                  
Number of common shares transferred and assigned for cancellation         1,000,000